Open access · US-GOV
via ClinicalTrials.gov Clinical trial
Pilot-testing the Effect of Magnetic Mitohormesis Therapy for Treating Frailty in Older Adults
Authors not listed
Auburn University · 2023
Abstract
Thirty (30) adults with limited physical function will be recruited to participate in a double-blind pilot randomized controlled crossover trial in which all participants will receive 12-weeks of twice weekly MMT treatment in the first (Phase 1) or second half (Phase 2) of the study period; during the control period, participants will receive sham treatment and will be blinded to the randomization.
◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:
Provenance
- Source
- ClinicalTrials.gov
- Canonical
- link ↗
- Fetched
- 2026-10-29 MST
Cite this
APA
Anonymous. (2023). Pilot-testing the Effect of Magnetic Mitohormesis Therapy for Treating Frailty in Older Adults. <em>Auburn University</em>. https://clinicaltrials.gov/study/NCT05930470
Vancouver
Anonymous. Pilot-testing the Effect of Magnetic Mitohormesis Therapy for Treating Frailty in Older Adults. Auburn University. 2023.
BibTeX
@misc{anon2023Pilott,
title = {Pilot-testing the Effect of Magnetic Mitohormesis Therapy for Treating Frailty in Older Adults},
author = {Anonymous},
journal = {Auburn University},
year = {2023},
}
Research neighborhood
References, citing works, and semantically nearest findings. Click a node to open it.
Related findings
Tainan Hospital, Ministry of Health and Welfare 2025
Open access · US-GOV
Exploring the Associations Among Frailty, Daily Physical Activity, Sleep, and Traditional Chinese Medicine Constitution in Taiwanese Older Adults, and Evaluating the Effects of Acupoint Stimulation Interventions
National Institute on Aging (NIA) 2004
Open access · US-GOV
Physical Exercise to Prevent Disability Pilot Study
Weill Medical College of Cornell University 2018
Open access · US-GOV
A Personalized Health Behavior System to Promote Well-Being in Older Adults (FITTLE)
GlaxoSmithKline 2023
Open access · US-GOV
A Randomized, Placebo-controlled, Double-Blind (Sponsor Unblind), Parallel Group, Single Dose, Dose Escalation Phase I Study in Sickle Cell Disease Participants, to Evaluate the Safety, Tolerability, and Pharmacokinetics of GSK4172239D
Animuscure Inc. 2025
Open access · US-GOV
A Multicenter, Randomized, Double-Blind, Placebo-controlled, Phase 2 Clinical Trial to Evaluate the Efficacy and Safety of AMC6156 in Patients With Sarcopenia
Pamukkale University 2024
Open access · US-GOV